Cor et vasa最新文献

{"title":"(Antithrombotic therapy in older patients)","authors":"P. Ostadal, M. Táborský, Z. Motovska","doi":"10.33678/cor.2023.037","DOIUrl":"https://doi.org/10.33678/cor.2023.037","url":null,"abstract":"V tomto suplementu Cor et Vasa je uveden v souladu se zavedenými pravidly český překlad odborného stanoviska Evropské kardiologické společnosti (ESC), které je zaměřeno na akutní, periprocedurální a dlouhodobou antitrombotickou léčbu u starších pacientů. Stárnutí populace v západních zemích je samozřejmě spojeno také s narůstajícími počty starších nemocných, kteří vyžadují antitrombotickou léčbu. Volba nejvhodnějších antitrombotik je však u starších nemocných komplikována řadou faktorů: (i) jedinci ve vyšším věku byli nedostatečně zastoupeni v řadě klinických studií, a proto současná evidence pro tuto populaci je často nedostatečná; (ii) starší nemocní mají více komorbidit, které je třeba zohlednit při výběru optimální léčby; (iii) vyšší věk je jedním z nejvýznamnějších rizikových faktorů pro krvácivé komplikace; (iv) u starších jedinců je třeba vždy zohlednit celkový biologický stav, faktory křehkosti („frailty“) a dlouhodobou prognózu. Považujeme proto za velmi přínosné věnovat specifi cká doporučení pro volbu nejvhodnější antitrombotické léčby právě u této populace. Odborné stanovisko ESC autorů Adreotti a spol. přináší podrobný přehled této problematiky. Lze velmi ocenit důraz na individualizaci léčby u starších pacientů, která je jistě ještě důležitější než u mladších jedinců. Autoři stanoviska citlivě zohledňují především vyšší riziko krvácení a z tohoto pohledu doporučují volit strategii antitrombotické léčby se zásadním ohledem na bezpečnost a minimalizaci rizika komplikací. Velký důraz je kladen také na zlepšení adherence k léčbě a na mnoha místech textu je uvedeno doporučení k užívání fi xních kombinací léků. Autoři českého překladu se zcela ztotožňují s většinou doporučení uvedených v originálním textu. Přesto nelze nezmínit některé body, které považujeme přinejmenším za diskutabilní. Především nepovažujeme za odůvodněné zvažovat preferenci prasugrelu před ticagrelorem u nemocných s akutním koronárním syndromem (AKS) na základě výsledků dominantně jediné klinické studie ISAR-REACT 5. Nejen že v této studii nebylo dostatečné zastoupení starších pacientů, ale především studie srovnávala dvě různé léčebné strategie (předléčení vs. nepředléčení inhibitorem P2Y 12 ), nikoli ticagrelor s prasugrelem a této studii se vytýká řada dalších metodologických nedostatků. Za další diskutabilní doporučení považujeme podávání trojité antitrombotické léčby po dobu jednoho až dvou týdnů po AKS u nemocných vyžadujících dlouhodobou antikoagulaci, což je agresivnější postup ve srovnání s G uidelines ESC pro AKS bez elevací úseku ST, kde je doporučená doba trojité léčby do 7 dnů (za hospitalizace) bez ohledu na věk. S vědomím nedostatečné evidence se domníváme, že právě u starších jedinců s vyšším rizikem krvácení může být kratší doba podávání trojité léčby spojena s klinickým benefi tem. Bez ohledu na výše uvedené námitky však odborné stanovisko ESC pro antitrombotickou léčbu u starších nemocných představuje komplexní pohled na tuto problematiku a může být ","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42380356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-myocardial infarction left ventricular intramyocardial dissecting hematoma","authors":"Adam Vejmělek, P. Nemec, P. Fila","doi":"10.33678/cor.2022.089","DOIUrl":"https://doi.org/10.33678/cor.2022.089","url":null,"abstract":"Background: Intramyocardial dissecting hematoma (IDH) is blood-fi lled cavitation in the cardiac wall that can occur as a complication of myocardial infarction, chest trauma, or percutaneous intervention. It can develop in the left ventricular free wall, the right ventricle, or the interventricular septum. Case report: The case report describes a patient with IDH as a rare complication of myocardial infarction. The patient was hospitalized for ongoing irritating cough three months after ST elevated myocardial infarction treated with percutaneous coronary intervention. The echocardiography showed the image of a pseudoaneurysm of the left ventricle. The patient underwent surgery where a cavitation inside the left ventricle myocardial wall communicating with the left ventricle was found. The inner and outer border of the cavitation included myocardium, therefore diagnosis of IDH was established. The communication and the cavitation were closed with pledgeted sutures and a direct suture with a mesh stripe. Postoperative hospitalization was without complications and the patient was dismissed the eighth day after the surgery. Discussion: Diagnosis of IDH consists of anamnestic information of myocardial infarction and assessment on echocardiography. On echocardiography the IDH shows as a neocavitation within the heart wall with an echo-lucent center. The differential diagnosis of IDH includes aneurysm, pseudoaneurysm of the heart, thrombus of the ventricle and trabeculae. Conclusion: The IDH is a post-infarction complication important to include in the differential diagnosis of newly formed cavitation inside the ventricle wall seen on echocardiography. Conservative management is suggested when the IDH is small and not growing. Surgery is indicated if the patient is unstable or the IDH is large or growing. Klíčová slova:","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44255335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Matrix metallopeptidase-9 prognostic role in STEMI patients after percutaneous coronary intervention (PCI) in one-year follow-up period","authors":"M. Kopytsya, Ya. V. Нilоva, I. Rodionova, A. Bilchenko, I. Kutia, B. Shelest","doi":"10.33678/cor.2022.109","DOIUrl":"https://doi.org/10.33678/cor.2022.109","url":null,"abstract":"","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46749788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive assessment of ventricular-arterial coupling: correlation between myocardial work and the pulse wave velocity parameters","authors":"A. Parlavecchio, R. Caminiti, G. Vetta, M. Magnocavallo, D. D. Della Rocca, R. Foti, Manuela Ajello, P. Crea, G. Dattilo, Massimo Siviglia, S. Postorino, A. Pangallo, F. Benedetto, C. Zito, S. Carerj","doi":"10.33678/cor.2022.102","DOIUrl":"https://doi.org/10.33678/cor.2022.102","url":null,"abstract":"Introduction: The myocardial work (MW) is a new echocardiographic method, based on the pressure-strain loop, which allows quantifying the cardiac performance. On the other hand, the pulse wave velocity (PWV) evaluates arterial stiffness, knowing that as the stiffness of an artery increases, the transmission velocity of the anterograde and the retrograde sphygmic wave increases","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45332728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inclisiran: new era of lipid-lowering therapy?","authors":"J. Beneš","doi":"10.33678/cor.2022.043","DOIUrl":"https://doi.org/10.33678/cor.2022.043","url":null,"abstract":"Dyslipidemia is the most frequent metabolic abnormality in western world population and a major risk fac- tor for coronary artery disease (CAD) development. Dyslipidemia treatment is still insuffi cient and achieving target LDL-level infrequent. Statins are a cornerstone of dyslipidemia management. Although statins are one of the safest drugs on the market, statin therapy can be associated with muscle symptoms and increased risk of DM development. Statin discontinuation is frequent, often driven by negative media coverage. Inclisiran is a therapeutic oligonucleotide that employs RNA interference and inhibits the translation of PCSK9-mRNA leading to long-lasting LDL-cholesterol lowering. LDL-cholesterol-lowering effect of inclisiran is reversed at the rate of approximately 2% per month, so the effect of a single dose persists up to approximately two years. When administered once every six months, inclisiran therapy decreases the level circulating LDL-cho- lesterol by 50–55% and up to 65% in selected patient populations. Inclisiran therapy is not associated with alterations in platelet count, blood lymphocyte, monocyte or neu- trophil count, does not cause alterations in blood TNF-alpha or IL-6 concentrations and does not induce relevant anti-drug antibodies. The only relevant side effect is an adverse reaction at the injection site. Inclisiran thus has the potential to become widely prescribed drug that will greatly contribute to dyslipidemia management and further decrease of CAD incidence.","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47883968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post‑infectious acute myocardial infarction following COVID‑19 infection in a young patient","authors":"R. Caminiti, G. Vetta, A. Parlavecchio, M. Magnocavallo, S. Postorino, S. Carerj, F. Benedetto","doi":"10.33678/cor.2022.064","DOIUrl":"https://doi.org/10.33678/cor.2022.064","url":null,"abstract":"It is now widely known that COVID-19 can also cause various extrapulmonary manifestations. Possible mechanisms of cardiovascular damage include direct myocardial damage due to hypercoagulability caused by systemic inflammation, which may also lead to destabilisation of coronary plaques. We present a case of a 30-year-old young man following asymptomatic COVID-19 infection, who was admitted to the emergency room of the Grande Ospedale Metropolitano di Reggio Calabria, Italy, with typical chest pain. The patient had no cardiovascular disease, cardiovascular risk factors including no family history of cardiovascular disease. Urgent coronary angiography showed critical stenosis of the middle-proximal portion of the left anterior descending artery (80%) with ulcerated plaque appearance. Regardless of cardiovascular risk factors, our case report emphasises the need to determine COVID-19 status in all patients with acute myocardial infarction during this pandemic.Copyright © 2023, CKS.","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46152539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of ascending aorta pseudoaneurysm in a patient with COVID-19","authors":"Sandra Rečičárová, P. Ivák, J. Pirk","doi":"10.33678/cor.2022.060","DOIUrl":"https://doi.org/10.33678/cor.2022.060","url":null,"abstract":"","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43056471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"(Cardiac tamponade as severe manifestation of angiosarcoma)","authors":"Daniel Baran, T. Roubíček, R. Polášek","doi":"10.33678/cor.2022.082","DOIUrl":"https://doi.org/10.33678/cor.2022.082","url":null,"abstract":"","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43422736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the Atherogenic Index of Plasma (AIP) a Cardiovascular Disease Marker?","authors":"Lutfu Askin, Okan Tanriverdi","doi":"10.33678/cor.2022.085","DOIUrl":"https://doi.org/10.33678/cor.2022.085","url":null,"abstract":"Numerous indicators have been used to diagnose and prognosticate cardiovascular disease (CVD). The athe- rogenic index of plasma (AIP) is a logarithmic conversion of triglyceride (TG) to high-density lipoprotein (HDL) molar concentrations. The close association between AIP and the size of lipoprotein particles may account for its excellent predictive value. AIP may be computed simply using a typical lipid profi le. It is a better predictor of lipoprotein particle size than that of individual lipids or the ratio of TG to HDL.","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47859610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the microRNA-221/222 Cluster Ushering in a New Age of Cardiovascular Diseases?","authors":"Lutfu Askin, Okan Tanriverdi","doi":"10.33678/cor.2022.050","DOIUrl":"https://doi.org/10.33678/cor.2022.050","url":null,"abstract":"In addition to regulating gene expression, microRNAs (MiRs) regulate messenger RNA degradation and translation rates. MiRs have a high expression in the cardiovascular (CV) system, indicating an important role in vascular health. The atherosclerotic process has been related to miRs-221 and -222. MiRs-221/222 possess anti-stenotic activity. MiR-221/222 may potentially serve as a marker for myocardial remodeling. There is still a long way yet before miRs-221/222 can be recognized as a potential therapeutic target. Identifi cation, validation, and understanding of the function of gene targets are all critical. Klíčová slova: Kardiovaskulární systém MikroRNA MiR-221/222 Působení proti tvorbě stenóz Remodelace","PeriodicalId":10787,"journal":{"name":"Cor et vasa","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46499185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}